
Please try another search
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.
Name | Age | Since | Title |
---|---|---|---|
Jay D. Kranzler | 64 | 2017 | Chairman of the Board |
Neil Herskowitz | 66 | 2015 | Non-Executive Independent Director |
Curtis G. Oltmans | 60 | 2021 | Independent Director |
Faith L. Charles | - | 2022 | Independent Director |
Lindsay Allan Rosenwald | 68 | 2015 | Executive Director |
Alexandra MacLean | 55 | 2022 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review